ATOSSA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
ATOSSA THERAPEUTICS, INC. (ATOS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.11% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-25
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.11%, a 3.07% decline from fiscal 2024.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.24%, a 5.36% decline from fiscal 2023.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.48%, a 25.84% increase from fiscal 2022.
- ATOSSA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.56%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|
| 2025-12-31 | 4.11% 10-K · filed 2026-03-25 |
| 2024-12-31 | 4.24% 10-K · filed 2026-03-25 |
| 2023-12-31 | 4.48% 10-K · filed 2025-03-25 |
| 2022-12-31 | 3.56% 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |